- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT06902298
Spersonalizowana ultradźwiękowa stymulacja mózgu do depresji (R61)
Spersonalizowana ultradźwiękowa stymulacja mózgu w celu depresji: badanie zaangażowania celu i efektów nastroju
This study will evaluate a new form of non-invasive brain stimulation for individuals with depression. Personalized low-intensity transcranial focused ultrasound stimulation will be delivered using a range of stimulation parameters during psychological and physiological monitoring. Individualized optimal targets will be selected using structural MRI and diffusion tractography. Brain target engagement will be evaluated using functional MRI.
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Szczegółowy opis
This R61 project has 3 aims:
- To determine whether stimulation engages the subcallosal cingulate (SCC) in an intensity-dependent manner
- To examine the degree of specificity of neuromodulation by contrasting the neural effects of stimulating two spatially distinct targets versus sham
- To evaluate safety, tolerability, and side effects
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Faza 2
- Faza 1
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Utah
-
Salt Lake City, Utah, Stany Zjednoczone, 84108
- University of Utah
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Age 18-65, any gender.
- Primary diagnosis of DMS-5 major depressive disorder (MINI).
- Current moderate-to-severe depressive episode, without psychotic features, lasting at least 2 months (MINI).
- Self-rated 16-item Quick Inventory of Depressive Symptomatology (QIDS) total score > 10.
- History of at least 2 failed trials of evidence-based antidepressant medication and/or psychotherapy (at least one trial during the current depressive episode).
- Stated willingness to comply with all study procedures and avoid changes to psychiatric treatments (medications, psychotherapy) for the duration of the study.
- For participants of reproductive potential: negative pregnancy test or use of highly effective contraception for at least 1 month prior to baseline; agreement to use such a method throughout the study.
- Capacity to provide informed consent; provision of a signed and dated consent form
- Currently are under the care of a licensed psychiatrist or other mental health care provider, or a licensed addiction medicine specialist and agrees to promptly inform the investigator or the study staff of any change in these providers.
- Agrees to allow any and all forms of communication between the investigators/study staff and any healthcare provider who currently provides and/or has provided service to the patient/subject within at least two years of study enrollment for the purposes of eligibility confirmation or in case of a safety event.
- Agrees to provide the name and verifiable contact information (email and mailing addresses, mobile and land-line phone numbers, as applicable) of at least two persons 22 years or older who reside within a 60-minute drive of the patient's residence. Subject agrees that in the event of a safety concern or event during study participation, research staff is at liberty to contact these individuals if the subject does not respond to contact attempts.
Exclusion Criteria:
- History of serious brain injury or other neurologic disorder.
- Poorly managed general medical condition.
- Pregnant or breast feeding.
- Implanted device in the head or neck.
- MRI intolerance or contraindication.
- Brain stimulation treatment such as ECT, TMS, or VNS (past month).
- Recent change in antidepressant treatments (past month).
- 8. Moderate-High Risk of Suicide according to the Columbia - Suicide Severity Rating Scale (C-SSRS) Screen Version - Recent (answers YES to Question 3 and NO to Question 6 (Moderate risk) or YES to Question 4, 5, or 6 (High risk)) and/or in the clinical judgement of the PI or a study psychiatrist
- Suicidal behavior (past year).
- Serious suicide attempt 33 (lifetime).
- Moderate-to-severe substance use disorder (MINI, past 3 months).
- Obsessive compulsive disorder, primary diagnosis (MINI, past month).
- Posttraumatic stress disorder, primary diagnosis (MINI, past month).
- Bipolar-spectrum disorder (MINI, lifetime).
- Schizophrenia-spectrum disorder (MINI, lifetime).
- Neurocognitive disorder (DSM-5, past year).
- Severe personality disorder.
- Clinically inappropriate for participation in the study as determined by the study team.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Podstawowa nauka
- Przydział: Randomizowane
- Model interwencyjny: Zadanie krzyżowe
- Maskowanie: Potroić
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: Group 1: SCC-ALIC
Low-intensity transcranial focused ultrasound stimulation (LTFUS) is delivered to the subgenual cingulate cortex (SCC) at the first stimulation visit, then LTFUS is delivered to the anterior limb of the internal capsule (ALIC) at the second stimulation visit. |
Low-intensity transcranial focused ultrasound delivered to subgenual cingulate cortex Low-intensity transcranial focused ultrasound delivered to anterior limb of internal capsule |
|
Eksperymentalny: Group 2: ALIC-SCC
Low-intensity transcranial focused ultrasound stimulation (LTFUS) is delivered to the anterior limb of the internal capsule (ALIC) at the first stimulation visit, then LTFUS is delivered to the subgenual cingulate cortex (SCC) at the second stimulation visit. |
Low-intensity transcranial focused ultrasound delivered to subgenual cingulate cortex Low-intensity transcranial focused ultrasound delivered to anterior limb of internal capsule |
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Modulation of SCC activity during SCC stimulation
Ramy czasowe: Days 14, 21, 28
|
Functional MRI is used to quantify modulation of SCC activity during SCC stimulation |
Days 14, 21, 28
|
|
Modulation of SCC activity during ALIC stimulation
Ramy czasowe: Days 14, 21
|
Functional MRI is used to quantify modulation of SCC activity during ALIC stimulation |
Days 14, 21
|
|
Study dropout
Ramy czasowe: From enrollment to the end of participation at 7 weeks
|
Dropout or withdrawal due to stimulation-related adverse effects |
From enrollment to the end of participation at 7 weeks
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
PANAS-X
Ramy czasowe: Immediately before and after each LTFUS on Days 14, 21, 28
|
Positive and Negative Affect Schedule, Expanded Form |
Immediately before and after each LTFUS on Days 14, 21, 28
|
|
MADRS
Ramy czasowe: Days 14, 21, 28, 35, 49
|
Montgomery-Asberg Depression Rating Scale |
Days 14, 21, 28, 35, 49
|
|
HDRS-6
Ramy czasowe: Days 0, 14, 15, 21, 22, 28, 29, 35, 49
|
6-item Hamilton Depression Rating Scale |
Days 0, 14, 15, 21, 22, 28, 29, 35, 49
|
|
IDS-SR
Ramy czasowe: Days 0, 14, 21, 28, 35, 49
|
Inventory of Depressive Symptomatology, Self-Rated |
Days 0, 14, 21, 28, 35, 49
|
|
GAD-7
Ramy czasowe: Days 0, 14, 21, 28, 35, 49
|
7-item Generalized Anxiety Disorder Scale |
Days 0, 14, 21, 28, 35, 49
|
|
YMRS
Ramy czasowe: Days 0, 14, 15, 21, 22, 28, 29, 35, 49
|
Young Mania Rating Scale |
Days 0, 14, 15, 21, 22, 28, 29, 35, 49
|
|
C-SSRS
Ramy czasowe: Days 0, 14, 15, 21, 22, 28, 29, 35, 49
|
Columbia Suicide Severity Rating Scale, Screen Version |
Days 0, 14, 15, 21, 22, 28, 29, 35, 49
|
|
GASE
Ramy czasowe: Days 15, 22, 29
|
Generic Assessment of Side Effects scale |
Days 15, 22, 29
|
|
MoCA
Ramy czasowe: Days 14, 15, 49
|
Montreal Cognitive Assessment |
Days 14, 15, 49
|
Współpracownicy i badacze
Sponsor
Współpracownicy
Śledczy
- Główny śledczy: Brian J Mickey, University of Utah
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Inne numery identyfikacyjne badania
- IRB_00148802R61
- R61MH134943 (Grant/umowa NIH USA)
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .